Keros Therapeutics, Inc. (KROS): who owns it and who trades it
As of Nov 16, 2026, KROS insiders reported 12 open-market sales worth $500K and 6 purchases worth $75.8K in the last 12 months, with 15% of the sale value made under pre-set 10b5-1 plans. The largest seller was Esther Cho (Vice president), with $124K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Keros Therapeutics
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Funds and insiders were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns KROS
131 funds and institutions reported KROS shares worth $215M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Nantahala Capital Management, LLC with 14.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2.82M | 14.31% | $30.2M | +107% |
| BlackRock, Inc. | 2.79M | 14.17% | $29.9M | +16% |
| AQR Capital Management LLC | 967,859 | 4.91% | $10.4M | +138% |
| Vanguard Capital Management LLC | 833,596 | 4.23% | $8.9M | +0% |
| Orbimed Advisors LLC | 759,155 | 3.85% | $8.1M | No change |
| Federated Hermes, Inc. | 700,427 | 3.55% | $7.5M | +2% |
| Vanguard Portfolio Management LLC | 652,635 | 3.31% | $7M | -4% |
| Mackenzie Financial Corp | 628,438 | 3.19% | $6.7M | +312% |
| Madison Avenue Partners, LP | 626,583 | 3.18% | $6.7M | No change |
| Qube Research & Technologies Ltd | 608,837 | 3.09% | $6.5M | -16% |
| Jacobs Levy Equity Management, Inc | 605,445 | 3.07% | $6.5M | -14% |
| State Street Corp | 541,193 | 2.74% | $5.8M | -4% |
| Geode Capital Management, LLC | 510,841 | 2.59% | $5.5M | -25% |
| Dimensional Fund Advisors LP | 460,541 | 2.34% | $4.9M | +43% |
| Citadel Advisors LLC | 396,098 | 2.01% | $4.2M | -3% |
| Renaissance Technologies LLC | 359,086 | 1.82% | $3.8M | -21% |
| D. E. Shaw & Co., Inc. | 267,460 | 1.36% | $2.9M | -48% |
| Bridgeway Capital Management, LLC | 265,017 | 1.34% | $2.8M | +36% |
| Nuveen, LLC | 247,756 | 1.26% | $2.7M | -5% |
| ADAR1 Capital Management, LLC | 246,818 | 1.25% | $2.6M | +154% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, KROS insiders reported $75.8K of open-market purchases and $500K of sales. 15% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Anne Prener | Director | Sale plan | 574 | $9.79 | $5.6K | Form 4 |
| Aug 18, 2026 | Annita Tanini | Vice president | Sale | 1,224 | $10.29 | $12.6K | Form 4 |
| Aug 18, 2026 | Lorena Raquel Lerner | Chief Scientific Officer | Sale | 3,568 | $10.29 | $36.7K | Form 4 |
| Aug 18, 2026 | Esther Cho | Chief Legal Officer | Sale | 4,485 | $10.29 | $46.2K | Form 4 |
| Aug 18, 2026 | Charles W. Newton | Director | Sale plan | 551 | $10.30 | $5.7K | Form 4 |
| Aug 17, 2026 | Jean Jacques Bienaime | Director | Purchase plan | 1,000 | $10.27 | $10.3K | Form 4 |
| Jul 15, 2026 | Jean Jacques Bienaime | Director | Purchase plan | 1,000 | $10.61 | $10.6K | Form 4 |
| Jun 15, 2026 | Jean Jacques Bienaime | Director | Purchase plan | 1,000 | $10.19 | $10.2K | Form 4 |
| Jun 11, 2026 | Charles W. Newton | Director | Sale plan | 550 | $10.04 | $5.5K | Form 4 |
| Jun 4, 2026 | Nima Farzan | Director | Sale plan | 2,625 | $10.73 | $28.2K | Form 4 |
| Jun 4, 2026 | Alpna Seth | Director | Sale plan | 2,625 | $10.72 | $28.1K | Form 4 |
| May 15, 2026 | Jean Jacques Bienaime | Director | Purchase plan | 1,000 | $10.58 | $10.6K | Form 4 |
| Apr 15, 2026 | Jean Jacques Bienaime | Director | Purchase plan | 1,000 | $11.70 | $11.7K | Form 4 |
| Mar 9, 2026 | Jean Jacques Bienaime | Director | Purchase plan | 2,000 | $11.21 | $22.4K | Form 4 |
| Feb 19, 2026 | Jasbir Seehra | CEO | Sale | 7,015 | $16.17 | $113K | Form 4 |
| Feb 18, 2026 | Lorena Raquel Lerner | Chief Science Officer | Sale | 3,873 | $16.35 | $63.3K | Form 4 |
| Feb 18, 2026 | Esther Cho | Vice president | Sale | 4,745 | $16.35 | $77.6K | Form 4 |
| Feb 18, 2026 | Keith Regnante | CFO | Sale | 4,739 | $16.35 | $77.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Esther Cho | SVP, General Counsel | – | $124K | Aug 18, 2026 |
| Jasbir Seehra | CHIEF EXECUTIVE OFFICER, Director | – | $113K | Feb 19, 2026 |
| Lorena Raquel Lerner | Chief Science Officer | – | $100K | Aug 18, 2026 |
| Keith Regnante | CHIEF FINANCIAL OFFICER | – | $77.5K | Feb 18, 2026 |
| Jean Jacques Bienaime | Director | $75.8K | – | Aug 17, 2026 |
| Nima Farzan | Director | – | $28.2K | Jun 4, 2026 |
| Alpna Seth | Director | – | $28.1K | Jun 4, 2026 |
| Annita Tanini | Corp. Controller & VP, Finance | – | $12.6K | Aug 18, 2026 |
| Charles W. Newton | Director | – | $11.2K | Aug 18, 2026 |
| Anne Prener | Director | – | $5.6K | Nov 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KROS short interest
Moderate short interest. 5.5% of KROS shares are sold short: about 1 share in 18. Over the last 12 reports the number of shares short went down 36%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.09M KROS shares were sold short, 5.5% of the shares outstanding, down 4.4% from the report before. At the average daily volume of 153,862 shares, buying them all back would take about 7.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.09M | 5.54% | -4% | 153,862 | 7.1 |
| Oct 15, 2026 | 1.14M | 5.73% | -1% | 174,612 | 6.5 |
| Sep 30, 2026 | 1.15M | 5.80% | -14% | 205,020 | 5.6 |
| Sep 15, 2026 | 1.34M | 6.77% | +15% | 147,052 | 9.1 |
| Aug 31, 2026 | 1.17M | 5.88% | +1% | 191,301 | 6.1 |
| Aug 14, 2026 | 1.15M | 5.79% | +17% | 242,951 | 4.7 |
| Jul 31, 2026 | 985,590 | 4.97% | -7% | 166,397 | 5.9 |
| Jul 15, 2026 | 1.06M | 5.37% | +3% | 259,282 | 4.1 |
| Jun 30, 2026 | 1.03M | 5.21% | -27% | 403,759 | 2.5 |
| Jun 15, 2026 | 1.41M | 7.14% | -7% | 213,268 | 6.6 |
| May 29, 2026 | 1.51M | 7.65% | -11% | 332,403 | 4.5 |
| May 15, 2026 | 1.70M | 8.64% | +20% | 366,493 | 4.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Keros Therapeutics company events
Keros Therapeutics filed 19 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementShared information with investors. Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 29, 2026AnnouncementShared information with investors. Filing
- Sep 28, 2026AnnouncementShared information with investors. Filing
- Sep 8, 2026AnnouncementKeros Therapeutics, Inc., a Delaware corporation, issued a press release announcing that the board of directors of the Company has approved a new stock repurchase program for up to $5 million of the Company’s common stock following receipt of a $20 million development milestone payment under the… Filing
- Aug 3, 2026AnnouncementShared information with investors. Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jul 30, 2026AnnouncementShared information with investors. Filing
- Jul 22, 2026LeadershipKeith Regnante resigned from his role as Chief Financial Officer of Keros Therapeutics, Inc., effective August 3, 2026, to pursue other opportunities. Filing
- Jun 25, 2026LeadershipThe board of directors of Keros Therapeutics, Inc., based upon a recommendation from the Nominating and Corporate Governance Committee of the Board, voted to appoint Anne Prener, M.D., Ph.D., as a director of the Company, effective on July 1, 2026. Filing
- Jun 3, 2026VoteReported shareholder vote results. Filing
- Jun 1, 2026AnnouncementShared information with investors. Filing
- May 14, 2026ResultsReleased financial results. Filing
- Mar 9, 2026AnnouncementKeros Therapeutics, Inc. issued a press release announcing that it has entered into an agreement with the Massachusetts General Hospital for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis within the HEALEY ALS MyMatch program, led by… Filing
- Mar 4, 2026AnnouncementShared information with investors. Filing
- Mar 4, 2026ResultsReleased financial results. Filing
- Feb 26, 2026LeadershipThe board of directors of Keros Therapeutics, Inc., based upon a recommendation from the Nominating and Corporate Governance Committee of the Board, voted to appoint Charles Newton as a director of the Company, effective on March 9, 2026. Filing
- Feb 18, 2026AnnouncementShared information with investors. Filing
- Jan 9, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Keros Therapeutics financials
Famous investors that hold KROS
5 of the 50 well-known investors we track reported holding KROS in their latest 13F filing. The largest position is Jim Simons's, worth $3.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 346,127 | $3.9M | 0.0% | -4% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 162,695 | $1.9M | 0.0% | -59% |
| Israel Englander · Millennium Management | Q3 2026 | 76,760 | $875K | 0.0% | -58% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 66,680 | $760K | 0.0% | +542% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 20,373 | $232K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KROS in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G/A | 9.1% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G/A | 9.1% |
Questions about Keros Therapeutics, Inc. (KROS) stock
Who owns the most KROS stock?
The largest reported owner of Keros Therapeutics, Inc. (KROS) is Nantahala Capital Management, LLC, with 14.3% of the company. In total, 131 funds and institutions reported holding KROS at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are KROS insiders buying or selling?
In the last 12 months, KROS insiders reported 6 open-market purchases worth $75.8K and 12 sales worth $500K. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in KROS?
As of Oct 30, 2026, 1.09M KROS shares were sold short, 5.5% of the shares outstanding, down 4.4% from the report before. At the average daily volume of 153,862 shares, buying them all back would take about 7.1 trading days (days to cover). See the history.
Which famous investors hold KROS?
5 of the 50 well-known investors we track reported KROS in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $3.9M. See all holders.
Executive pay
Keros Therapeutics's chief executive was paid a total of $2.5M for the year ended Dec 31, 2025, down 60% from $6.3M the year before. In the last 12 months, Keros Therapeutics's executives and directors bought $75.8K of stock on the open market and sold $500K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.